regorafenib + TAS-102-Medicago-influenza (H5N1)

The name "regorafenib + TAS-102-Medicago-influenza (H5N1)" appears to be an erroneous or composite string combining two distinct therapeutic contexts: the combination of **regorafenib** and **TAS-102** (trifluridine and tipiracil) used in colorectal cancer research, and the **Medicago plant-based H5N1 influenza virus-like particle (VLP) vaccine**. Regorafenib is an oral multi-kinase inhibitor targeting VEGFR, TIE2, and KIT pathways, while TAS-102 is a cytotoxic combination chemotherapy consisting of a thymidine-based nucleoside analog and a thymidine phosphorylase inhibitor. The Medicago H5N1 vaccine is a recombinant vaccine produced in *Nicotiana benthamiana* plants, consisting of virus-like particles that mimic the structure of the influenza virus to elicit an immune response against the hemagglutinin (H5) protein. There is no known clinical trial or pharmaceutical product that combines these specific oncology agents with a pandemic influenza vaccine.

Brand names

StivargaLonsurf

Other names

trifluridine + tipiracilH5 VLP vaccineH-5 VLP vaccineH 5 VLP vaccinePlant-based H5 VLP influenza vaccine